Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies

Next Previous
Search
Trial Profile

A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SGN CD70A (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Renal cell carcinoma
  • Focus Adverse reactions; First in man
  • Sponsors Seagen

    • Most Recent Events

    • 09 Jan 2019 Results (n=18) published in the Cancer.
    • 22 Aug 2018 Results (n=20) published in the Investigational New Drugs.
    • 22 Aug 2018 Status changed from discontinued to completed, according to results published in the Investigational New Drugs.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top